| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adapting the drivers to the road: a new strategy for cancer evolution?
|
Touat, M.
|
|
|
26 |
5 |
p. 827-829
|
article
|
| 2 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, J.S.
|
|
|
26 |
5 |
p. 943-949
|
article
|
| 3 |
An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European research more competitive again
|
Dittrich, C.
|
|
|
26 |
5 |
p. 829-832
|
article
|
| 4 |
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200 †
|
Chu, Q. S.-C.
|
|
|
26 |
5 |
p. 973-981
|
article
|
| 5 |
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial †
|
Fuchs, C.S.
|
|
|
26 |
5 |
p. 921-927
|
article
|
| 6 |
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) †
|
Blumenschein Jr, G.R.
|
|
|
26 |
5 |
p. 894-901
|
article
|
| 7 |
A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
|
|
|
|
26 |
5 |
p. 1038-1039
|
article
|
| 8 |
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors
|
Serpico, D.
|
|
|
26 |
5 |
p. 838-847
|
article
|
| 9 |
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma
|
Barta, S.K.
|
|
|
26 |
5 |
p. 958-966
|
article
|
| 10 |
Choosing a better end point for trials of bone-protective agents
|
Leibowitz-Amit, R.
|
|
|
26 |
5 |
p. 1032-1033
|
article
|
| 11 |
Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer
|
Rossi, G.
|
|
|
26 |
5 |
p. 1035-1036
|
article
|
| 12 |
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase
|
Isambert, N.
|
|
|
26 |
5 |
p. 1005-1011
|
article
|
| 13 |
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis
|
Louie, K.S.
|
|
|
26 |
5 |
p. 848-864
|
article
|
| 14 |
Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions †
|
van Leeuwen, R.W.F.
|
|
|
26 |
5 |
p. 992-997
|
article
|
| 15 |
Editorial board
|
|
|
|
26 |
5 |
p. ii-iii
|
article
|
| 16 |
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study †
|
Monk, B.J.
|
|
|
26 |
5 |
p. 914-920
|
article
|
| 17 |
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial
|
Hebbar, M.
|
|
|
26 |
5 |
p. 1040
|
article
|
| 18 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome
|
Favero, F.
|
|
|
26 |
5 |
p. 880-887
|
article
|
| 19 |
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) †
|
Gourgou-Bourgade, S.
|
|
|
26 |
5 |
p. 873-879
|
article
|
| 20 |
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) †
|
Bellera, C.A.
|
|
|
26 |
5 |
p. 865-872
|
article
|
| 21 |
How can I validate a nomogram? Show me the model
|
Collins, G.S.
|
|
|
26 |
5 |
p. 1034-1035
|
article
|
| 22 |
Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)
|
Chihara, D.
|
|
|
26 |
5 |
p. 966-973
|
article
|
| 23 |
Letter to the editor concerning ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’
|
Carlsson, S.
|
|
|
26 |
5 |
p. 1031
|
article
|
| 24 |
Letter to the editor concerning ‘Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA’
|
Foglietta, J.
|
|
|
26 |
5 |
p. 1033-1034
|
article
|
| 25 |
Long-term effects of inhaled budesonide on screening-detected lung nodules
|
Veronesi, G.
|
|
|
26 |
5 |
p. 1025-1030
|
article
|
| 26 |
Molecular phenotypes of DCIS predict overall and invasive recurrence †
|
Williams, K.E.
|
|
|
26 |
5 |
p. 1019-1025
|
article
|
| 27 |
Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapy
|
van Gijn, W.
|
|
|
26 |
5 |
p. 928-935
|
article
|
| 28 |
Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort study
|
Mattsson, T.O.
|
|
|
26 |
5 |
p. 981-986
|
article
|
| 29 |
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
|
Oldenburg, J.
|
|
|
26 |
5 |
p. 833-838
|
article
|
| 30 |
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
|
Wong, A.L.
|
|
|
26 |
5 |
p. 998-1005
|
article
|
| 31 |
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
|
Fu, S.
|
|
|
26 |
5 |
p. 1012-1018
|
article
|
| 32 |
Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases
|
de Baère, T.
|
|
|
26 |
5 |
p. 987-991
|
article
|
| 33 |
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial †
|
Pujol, J.-L.
|
|
|
26 |
5 |
p. 908-914
|
article
|
| 34 |
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
|
Sugawara, S.
|
|
|
26 |
5 |
p. 888-894
|
article
|
| 35 |
Recent developments in the implementation of novel designs for early-phase combination studies
|
Wages, N.A.
|
|
|
26 |
5 |
p. 1036-1037
|
article
|
| 36 |
Reply to the letter to the editor ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’ by Louie et al.
|
Louie, K.S.
|
|
|
26 |
5 |
p. 1031-1032
|
article
|
| 37 |
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population †
|
Renfro, L.A.
|
|
|
26 |
5 |
p. 950-958
|
article
|
| 38 |
Table of Contents
|
|
|
|
26 |
5 |
p. iv-vi
|
article
|
| 39 |
The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC
|
Takahashi, Y.
|
|
|
26 |
5 |
p. 935-942
|
article
|
| 40 |
Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis
|
Janssen-Heijnen, M.L.G.
|
|
|
26 |
5 |
p. 902-907
|
article
|
Journal description